Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT05198934	TitleSotorasib y panitumumab frente a la elección del investigador para participantes con sarcoma de rata de Kirsten (KRAS) con mutación p.G12C (CodeBreak 300)	Fase Fase 3	Date Added 2022-01-20	Ubicación Alabama, United States California, United States District of Columbia, United States Florida, United States Georgia, United States Michigan, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Francia Alemania Greece Italia Japón Corea, República de Mexico España Taiwán Reino Unido	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05194735	TitleEstudio de fase I/II de células T autólogas que expresan receptores de células T (TCR) en sujetos con tumores sólidos	Fase Fase 1	Date Added 2022-01-18	Ubicación Texas, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Aldesleukin (IL-2), Neoantigen specific TCR-T cell drug product	Etiquetas MSS/ MMRp
NCT ID NCT05167409	TitleA Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer	Fase Fase 2	Date Added 2021-12-22	Ubicación Arizona, United States Colorado, United States New Jersey, United States Virginia, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas ALX148, cetuximab, Evorpacept (ALX148), Pembrolizumab, Erbitux, Keytruda	Etiquetas MSS/ MMRp
NCT ID NCT05141721	TitleA Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer	Fase Fase 2	Date Added 2021-12-02	Ubicación Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Maryland, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin	Etiquetas MSS/ MMRp
NCT ID NCT05141474	TitleEvaluación de la seguridad y tolerabilidad de la terapia ex vivo con linfocitos infiltrantes de tumor (TIL) seleccionados por neoantígenos de nueva generación en tumores epiteliales avanzados y tumores sólidos resistentes al bloqueo de puntos de control inmunitario (ICB).	Fase Fase inicial 1	Date Added 2021-12-02	Ubicación España	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas Interleukin-2, NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05107674	TitleA Study of NX-1607 in Adults With Advanced Malignancies	Fase Fase 1	Date Added 2021-11-04	Ubicación California, United States Colorado, United States Illinois, United States North Carolina, United States Oklahoma, United States Texas, United States Virginia, United States Washington, United States Reino Unido	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas NX-1607	Etiquetas MSS/ MMRp
NCT ID NCT05019534	TitleTolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer	Fase Fase 1	Date Added 2021-08-25	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Camrelizumab, Cetuximab Injection [Erbitux], Vemurafenib Oral Tablet [Zelboraf]	Etiquetas MSS/ MMRp
NCT ID NCT04991948	TitleStudy of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer	Fase Fase 1	Date Added 2021-08-05	Ubicación Florida, United States Bélgica	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas CYAD-101, FOLFOX, Pembrolizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04984369	TitleThe Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment	Fase Fase 2	Date Added 2021-07-30	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Cetuximab Injection [Erbitux], HLX208	Etiquetas MSS/ MMRp
NCT ID NCT04973163	TitleEstudio para probar diferentes dosis de BI 1823911 solo y combinado con otros medicamentos en personas con diferentes tipos de cáncer avanzado con mutación KRAS.	Fase Fase 1	Date Added 2021-07-22	Ubicación Texas, United States Bélgica España Reino Unido	Prior IO Allowed No	CRC-directed No	Status Activo, no recluta	Drogas BI 1701963, BI 1823911, Midazolam	Etiquetas MSS/ MMRp

Showing 121 to 130 of 299 entries